Novartis, Amgen Shares Drop After Disappointing Clinical Trial Results
Shares of Novartis (NVS) fell nearly 13% on Tuesday after the pharmaceutical company reported disappointing results from two clinical trials. An experimental drug called del-desiran failed to improve a key indicator for patients with myotonic dystrophy, and another drug targeting cholesterol also did not meet its goals in reducing cardiovascular events. Amgen (AMGN) shares dropped 9% as investors worried about the implications of Novartis' results on similar drugs under development. The decline weighed heavily on the Dow Jones Industrial Average due to Amgen's significant weighting within the index. Despite these setbacks, Novartis remains committed to advancing its del-desiran program and expects sales growth of 5-6% annually through 2030. The stock market reaction highlights how clinical trial outcomes can significantly impact pharmaceutical companies' valuations by affecting investor expectations for future product launches and revenue.
